Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy

JAMA

Volumn 300, Issue 5, 2008, Pages 530-539

  Boulle, Andrew ^a   Van Cutsem, Gilles ^b   Cohen, Karen ^a   Hilderbrand, Katherine ^a,b   Mathee, Shaheed ^c   Abrahams, Musaed ^c   Goemaere, Eric ^b   Coetzee, David ^a   Maartens, Gary ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c WESTERN CAPE DEPARTMENT OF AGRICULTURE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DEATH; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; TUBERCULOSIS; VIROLOGY; VIRUS LOAD;

EID: 48749098848     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.5.530     Document Type: Article

References (36)

1. Brinkhof MW, Egger M, Boulle A, et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis. 2007;45(11):1518-1521.
2. Boulle A, Zweigenthal V, Hilderbrand K, Magwaca N, Coetzee D. Incidence of tuberculosis pre- and post-ART in a setting of high tuberculosis-HIV comorbidity. Paper presented at: 15th International AIDS Conference. July 11-16, 2004; Bangkok, Thailand; 2004. Abstract MoPeB 3239.
3. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20(12):1605-1612.
4. Corbett EL, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet. 2006;367(9514):926-937.
5. Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS. 2007;21(10):1301-1308.
6. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access. Geneva, Switzerland: World Health Organization; 2006.
7. Centers for Disease Control and Prevention Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors; 2004. Version 1.20.04. http://www.nccc.ucsf.edu/Clinical_Resources/Guidelines/ PDFs/tbhiv.pdf. Accessed July 11, 2008.
8. Patel A, Patel K, Patel J, Shah N, Patel B, Rani S. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr. 2004;37(1):1166-1169.
9. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS. 2005;19(14):1481- 1486.
10. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS. 2006;20(1):131-132.
11. McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis. 2007;196(suppl 1):S63-S75.
12. López-Cortés LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41(9):681-690.
13. Ramachandran G, Hemanthkumar AK, Rajasekaran S, et al. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J Acquir Immune Defic Syndr. 2006;42(1):36-41.
14. Cohen K, van Cutsem G, Boulle A, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother. 2008;61(2):389-393.
15. Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr. 2001;28(5):450-453.
16. Centers for Disease Control and Prevention. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. 2007. http://www.cdc.gov/tb/ TB_HIV_Drugs/default.htm. Published December 2007. Accessed July 11, 2008.
17. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191(6):825-829.
18. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363(9417):1253-1263.
19. Boulle A, Orrel C, Kaplan R, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther. 2007;12(5):753-760.
20. Oliva J, Moreno S, Sanz J, et al. Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis. AIDS. 2003;17(4):637-638.
21. ManosuthiW,Ruxrungtham K, Likanonsakul S, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis. 2007;44(1):141-144.
22. Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S. Standard-dose efavirenz vs standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med. 2008;9(5):294-299.
23. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18(6):887-895.
24. The 2005 HIV Antenatal Provincial and Area Surveys Western Cape. Cape Town, South Africa: Department of Health Provincial Administration of the Western Cape; 2006.
25. Coetzee D, Hilderbrand K, Boulle A, Draper B, Abdullah F, Goemaere E. Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa. Bull World Health Organ. 2005;83(7):489-494.
26. Coetzee D, Boulle A, Hilderbrand K, Asselman V, Van Cutsem G, Goemaere E. Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS. 2004;18(suppl 3):S27-S31.
27. Provincial Government of the Western Cape. Antiretroviral Treatment Protocol. Cape Town, South Africa: Provincial Government of the Western Cape; 2004. http://web.uct.ac.za/depts/epi/artrollout/files/ ARV%20protocol%20version%202%20may%202004.PDF. Accessed July 11, 2008.
28. National Department of Health. South African National Antiretroviral Treatment Guidelines. Pretoria, South Africa: National Dept of Health; 2004.
29. Saranchuk P, Boulle A, Hilderbrand K, et al. Evaluation of a diagnostic algorithm for smear-negative pulmonary tuberculosis in HIV-infected adults. S Afr Med J. 2007;97(7):517-523.
30. van Oosterhout JJ, Kumwenda JJ, Beadsworth M, et al. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. Antivir Ther. 2007;12(4):515-521.
31. Pedral-Sampaio DB, Alves CR, Netto EM, Brites C, Oliveira AS, Badaro R. Efficacy and safety of efavirenz in HIV patients on rifampin for tuberculosis. Braz J Infect Dis. 2004;8(3):211-216.
32. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy. AIDS. 1998;12(13):1619-1624.
33. Martin DJ, Sim JG, Sole GJ, et al. CD4- lymphocyte count in African patients co-infected with HIV and tuberculosis. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(4):386-391.
34. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (ICoNA) study. J Infect Dis. 2002;185(8):1062-1069.
35. Keiser P, Nassar N, White C, Koen G, Moreno S. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials. 2002;3(4):296-303.
36. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146(8):564-573.